Discover what Novelmab is, how its dual targeting of PD‑1 and a tumor‑associated antigen works, and why this next‑generation bispecific antibody is generating buzz in oncology for potentially overcoming resistance to standard immunotherapy in solid tumors.
Discover how next‑generation KRAS inhibitors are overturning the “undruggable” myth in oncology. Learn why KRAS was so hard to target, how covalent KRAS G12C inhibitors like sotorasib and adagrasib work, and what this revolution means for personalized cancer treatment.